PDL BioPharma, Inc. (NASDAQ:PDLI) Files An 8-K Regulation FD DisclosureItem 7.01 Regulation FD Disclosure
On October 30, 2017, PDL BioPharma, Inc. (the "Company") issued a press release in response to the Neos Therapeutics, Inc. (“Neos”) (NASDAQ: NEOS) Board of Directors’ rejection of the Company’s October 26 proposal to acquire Neos for $10.25 per share in cash. A copy of the Company's press release has been posted to the Company's website and is attached hereto as Exhibit 99.1.
Limitation of Incorporation by Reference
In accordance with the General Instruction B.2. of Form 8-K, this information, including the Exhibit, is furnished to Item 7.01 and shall not be deemed to be "filed" for the purpose of Section 18 of the Securities Exchange Act of 1934, as amended, or otherwise subject to the liabilities of that section. The information in this Item 7.01 of this Current Report on Form 8-K will not be deemed an admission as to the materiality of any information that is required to be disclosed solely by Regulation FD.
Item 9.01 Financial Statements and Exhibits.
The following exhibit is furnished with this report:
|
Exhibit No. |
Description |
|
99.1 |
Cautionary Statements
This filing and the press release include "forward-looking statements" within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended. Each of these forward-looking statements involves risks and uncertainties. Actual results may differ materially from those, express or implied, in these forward-looking statements. Important factors that could impair the value of the Company's assets or business, are disclosed in the "Risk Factors" contained in the Company's Annual Report on Form 10-K, filed with the Securities and Exchange Commission on March 1, 2017. All forward-looking statements are expressly qualified in their entirety by such factors. We do not undertake any duty to update any forward-looking statement except as required by law.
PDL BIOPHARMA, INC. ExhibitEX-99.1 2 pdli-201710308xkex991b.htm PRESS RELEASE Exhibit Exhibit 99.1PDL BioPharma Issues Statement in Response to Neos Therapeutics Rejection of PDL Acquisition ProposalINCLINE VILLAGE,…To view the full exhibit click here
About PDL BioPharma, Inc. (NASDAQ:PDLI)
PDL BioPharma, Inc., formerly Protein Design Labs, Inc., manages a portfolio of patents and royalty assets, consisting of its Queen et al. patents, license agreements with various biotechnology and pharmaceutical companies, and royalty and other assets acquired. The Company provides non-dilutive growth capital and financing solutions to late-stage public and private healthcare companies and offers immediate financial monetization of royalty streams to companies, academic institutions and inventors. It evaluates its investments based on the quality of the income generating assets and potential returns on investment. It is focused on intellectual property asset management, acquiring income generating assets and maximizing value for its stockholders, among others. It receives royalties on sales of over ten humanized antibody products, which include Avastin, Herceptin, Xolair, Kadcyla, Tysabri, Actemra, Gazyva and Entyvio all of which are approved for use.